Bifidobacterium proliferation promoter, and food product and pharmaceutical preparation including the same

Combining 1-kestose with specific nutritional components addresses the mixed growth effects of bifidobacteria, achieving synergistic or countervailing growth promotion in foods and pharmaceuticals.

JP2024165869APending Publication Date: 2024-11-28FUJITA HEALTH UNIVERSITY +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023082426
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-18
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Certain nutritional components can either promote or inhibit the growth of bifidobacteria, and their effects can be counteracting, making it challenging to achieve consistent growth promotion in foods and pharmaceuticals.

Method used

A combination of 1-kestose with specific nutritional components such as isomaltodextrin, glucomannan, levan, β-glucan, rutin, quercetin, catechin, hesperidin, daidzein, p-coumaric acid, caffeic acid, vanillin, biotin, niacin, pantothenic acid, riboflavin, vitamin E, vitamin D, arachidonic acid, α-linolenic acid, γ-aminobutyric acid, soybean protein, whey protein, lactoferrin, calcium, and potassium is used to synergistically or countervailingly promote bifidobacteria growth.

Benefits of technology

The combination enhances or offsets the growth-promoting effects of bifidobacteria, achieving synergistic or countervailing outcomes depending on the nutritional component, promoting the growth of various Bifidobacterium species.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024165869000001_ABST
    Figure 2024165869000001_ABST
Patent Text Reader

Abstract

To provide a bifidobacterium proliferation promoter with a synergistic or counteractive effect through combining 1-kestose and a nutrient component, the promoter including a combination capable of further exerting a synergistic proliferation promotion effect from a bifidobacterium proliferation promotion effect at a case of a single intake of a nutrient component or a combination capable of further exerting a bifidobacterium proliferation promotion effect through counteracting a bifidobacterium proliferation inhibitory effect at a case of a single intake of a nutrient component.SOLUTION: A bifidobacterium proliferation promoter is a synergistic or counteractive bifidobacterium proliferation promoter including 1-kestose and a nutrient component. The nutrient component is one or more kinds of components selected from a prescribed dietary fiber, a prescribed polyphenol, a prescribed vitamin, a prescribed fat, a prescribed amino-acid, a prescribed protein, and a prescribed mineral.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a bifidobacterium growth promoter, and to a food and a pharmaceutical product containing the same. [Background technology]

[0002] Bifidobacteria are bacteria belonging to the genus Bifidobacterium, and are known to be good bacteria in the intestinal flora, producing lactic acid and acetic acid to improve or maintain a healthy intestinal environment. Bifidobacteria are also used as probiotics that can be ingested in the form of food, etc.

[0003] Furthermore, 1-kestose is known as one of the prebiotics that has the effect of promoting the growth of the above-mentioned bifidobacteria (Patent Document 1: Japanese Patent Application Laid-Open No. 2005-306781). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2005-306781 A [Non-patent literature]

[0005] [Non-Patent Document 1] D.Gwiazdowska.et al. “The impact of polyphenols on Bifidobacterium growth” Acta Biochimica Polanica, (PL), Polish Biochemical Society and Polish Academy of Sciences, 2015, Vol.62, No.4, p.895-901 Summary of the Invention [Problem to be solved by the invention]

[0006] Incidentally, foods containing specific nutritional components, collectively referred to as health foods, or dietary supplements, nutritional supplements, supplements, etc., which are consumed in anticipation of supplementing the nutritional components or achieving specific functions, are now in widespread use. Examples of nutritional components contained in these foods include carbohydrates, dietary fiber, polyphenols, vitamins, lipids, amino acids, proteins, minerals, etc. Among these nutritional components, some are known to have a proliferation-promoting effect on bifidobacteria, while others may inhibit the initial proliferation of bifidobacteria depending on the ingested concentration, etc. (Non-Patent Document 1). [Means for solving the problem]

[0007] The present inventors have studied the effects of these nutritional components on bifidobacteria, and further studied the effects of nutritional components plus 1-kestose on bifidobacteria. As a result, they have found that there are components whose growth-promoting effect on bifidobacteria confirmed by the nutritional components alone is further expressed as a synergistic growth-promoting effect when combined with 1-kestose (details will be described later, but this effect is defined as a synergistic growth-promoting effect), or whose growth-inhibiting effect on bifidobacteria confirmed by the nutritional components alone is counterbalanced by the combined use of 1-kestose, resulting in a further growth-promoting effect on bifidobacteria (details will be described later, but this effect is defined as a countervailing growth-promoting effect), leading to the present invention.

[0008] In other words, the present invention aims to provide a synergistic or countervailing bifidobacterial growth promoter, including a combination of 1-kestose and a nutritional component, which can further increase the bifidobacterial growth-promoting effect of the nutritional component when taken alone, by further increasing the synergistic growth-promoting effect, or a combination in which the bifidobacterial growth-inhibiting effect of the nutritional component when taken alone is offset, thereby increasing the bifidobacterial growth-promoting effect, as well as foods and pharmaceuticals containing the same.

[0009] The present invention solves the above problems by the solution means described below as one embodiment.

[0010] One embodiment of the bifidobacterial growth promoter of the present invention is a synergistic or countervailing bifidobacterial growth promoter containing 1-kestose and a nutritional component, characterized in that the nutritional component is one or more types of dietary fiber selected from isomaltodextrin, glucomannan, levan, and β-glucan.

[0011] Furthermore, one embodiment of the bifidobacterial growth promoter according to the present invention is a synergistic or countervailing bifidobacterial growth promoter comprising 1-kestose and a nutritional component, characterized in that the nutritional component is one or more polyphenols selected from rutin, quercetin, catechin, hesperidin, daidzein, p-coumaric acid, caffeic acid, and vanillin.

[0012] Furthermore, one embodiment of the bifidobacterial growth promoter of the present invention is a synergistic or countervailing bifidobacterial growth promoter comprising 1-kestose and a nutritional component, characterized in that the nutritional component is one or more vitamins selected from biotin, niacin, pantothenic acid, riboflavin, vitamin E, and vitamin D, derivatives of these vitamins, and salts of the vitamins and the derivatives.

[0013] Furthermore, one embodiment of the bifidobacterial growth promoter of the present invention is a synergistic or countervailing bifidobacterial growth promoter comprising 1-kestose and a nutritional component, characterized in that the nutritional component is one or more lipids selected from arachidonic acid, α-linolenic acid, and compounds having these fatty acids as constituent fatty acids.

[0014] Furthermore, one embodiment of the bifidobacterial growth promoter of the present invention is a synergistic or countervailing bifidobacterial growth promoter containing 1-kestose and a nutritional component, characterized in that the nutritional component is one or more amino acids or proteins selected from γ-aminobutyric acid, soy protein, whey protein, and lactoferrin.

[0015] Furthermore, one embodiment of the bifidobacterial growth promoter of the present invention is a synergistic or countervailing bifidobacterial growth promoter containing 1-kestose and a nutritional component, characterized in that the nutritional component is one or more minerals selected from calcium and potassium.

[0016] Furthermore, the bifidobacterium growth promoter according to the present invention can also be a synbiotic that contains bifidobacteria in addition to the 1-kestose and the nutritional components.

[0017] The food product according to the present invention is provided as a food product containing the bifidobacterium growth promoter according to the present invention.The pharmaceutical product according to the present invention is provided as a pharmaceutical product containing the bifidobacterium growth promoter according to the present invention. Effect of the Invention

[0018] According to the present invention, by using 1-kestose in combination with a predetermined nutritional component, a synergistic or countervailing effect of promoting the proliferation of bifidobacteria can be obtained. [Brief description of the drawings]

[0019] [Figure 1] Figures 1A, 1B, and 1C are explanatory diagrams illustrating the synergistic effect of promoting the proliferation of bifidobacteria and the countervailing effect of promoting the proliferation of bifidobacteria according to the present invention. Figure 1A is a graph showing an example of the amount of proliferation of bifidobacteria. Figure 1B is a graph showing an example of the synergistic effect of promoting the proliferation of bifidobacteria. Figure 1C is a graph showing an example of the countervailing effect of promoting the proliferation of bifidobacteria. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Hereinafter, an embodiment of the present invention will be described.

[0021] The bifidobacterial growth promoter according to this embodiment is a synergistic or countervailing bifidobacterial growth promoter containing 1-kestose and a specific nutritional component. 1-kestose may be abbreviated as "Kes". First, the synergistic and countervailing bifidobacterial growth promotion effects according to the present invention are defined. FIG. 1A shows an example of the amount of bifidobacterial growth at a certain time point (e.g., 24 hours, 48 ​​hours, etc.) after the start of culture when bifidobacteria are cultured in a specific medium, as a turbidity increase amount that represents the net turbidity obtained by subtracting the turbidity measurement value at the start of culture from the turbidity measurement value of the medium at that time point.

[0022] Point a represents an example of culture using only the basal medium components. Point b represents an example of culture using the basal medium components with the addition of a specified nutritional component. Point b shows a larger increase in turbidity than point a, and the nutritional component has the effect of promoting the growth of bifidobacteria. Point c represents an example of culture using the basal medium components with the addition of 1-kestose. Point c shows a larger increase in turbidity than point a, and 1-kestose has the well-known effect of promoting the growth of bifidobacteria. Point d represents an example of culture using the basal medium components with the addition of 1-kestose and the specified nutritional component.

[0023] In this case, the difference in the turbidity increase between points a and b, represented by the line ab, represents the growth-promoting effect of a nutritional component alone on bifidobacteria, in other words, the growth-promoting effect of the nutritional component in the absence of 1-kestose. In contrast, the difference in the turbidity increase between points c and d, represented by the line cd, represents the growth-promoting effect of a combination of 1-kestose and a nutritional component, in other words, the growth-promoting effect of the nutritional component in the presence of 1-kestose. Therefore, by comparing the effect represented by the line ab with the effect represented by the line cd, it is possible to evaluate whether or not the growth-promoting effect of a nutritional component alone on bifidobacteria can be further enhanced as a synergistic growth-promoting effect by using 1-kestose in combination with a nutritional component, that is, whether or not there is a synergistic growth-promoting effect of using 1-kestose in combination with a nutritional component.

[0024] Specifically, the slope of the line ab, that is, the value b / a obtained by dividing the turbidity increase at point b by the turbidity increase at point a, and the slope of the line cd, that is, the value d / c obtained by dividing the turbidity increase at point d by the turbidity increase at point c, are When (b / a) ≧ 1.0, (d / c) / (b / a) > 1.0 is satisfied. It can be evaluated that the combination of 1-kestose and the nutritional components has a synergistic effect of promoting the proliferation of bifidobacteria (see Figure 1B). In this case, (d / c) naturally becomes > 1.0.

[0025] The presence or absence of a countervailing effect of promoting the growth of bifidobacteria by using 1-kestose in combination with a nutritional component can also be evaluated in a similar manner. That is, in the example shown in FIG. 1A, point b is replaced with an example in which the increase in turbidity is smaller than that of point a (not shown). In this case, the nutritional component has an effect of inhibiting the growth of bifidobacteria, and the value of b / a is smaller than 1.0, so that When (b / a) < 1.0 and (d / c) / (b / a) > 1.0 are satisfied, the combination of 1-kestose and the nutritional component can be evaluated as having a countervailing effect of promoting the growth of bifidobacteria (see FIG. 1C). This countervailing effect of promoting the growth of bifidobacteria is defined as an effect that can be exerted by combining 1-kestose with a nutritional component, as the inhibitory effect of the nutritional component alone on the growth of bifidobacteria is countervailed and the effect of promoting the growth of bifidobacteria is further countervailed, so that (d / c) > 1.0. Therefore, the countervailing effect according to the present invention can be understood as an effect that exceeds the simple cancellation of the inhibitory effect of one and the promoting effect of the other, and in a broad sense, can be included in the category of a synergistic effect.

[0026] Next, the bifidobacteria whose growth is promoted by the present invention are bacteria belonging to the genus Bifidobacterium, and include Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium The bifidobacterium growth promoter according to the present invention promotes the growth of at least one type of bacteria, as exemplified herein. The bifidobacterium growth promoter according to the present embodiment exhibits a growth promoting effect on multiple types of bacteria, including at least Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium infantis (see Examples).

[0027] Next, 1-kestose is a fructooligosaccharide in which one molecule of fructose is bound to sucrose, and the fructose is bound by β(2,1) to the fructose in sucrose. It is known that 1-kestose has a growth-promoting effect on bifidobacteria, but the present invention represents a dramatic technological advance in that the combined use of 1-kestose and a specific nutritional component has a synergistic or countervailing effect on the growth of bifidobacteria that exceeds the effects of both components on bifidobacteria.

[0028] 1-kestose is a known chemical substance and is available commercially, so that the commercially available products can be used as is as the formulation components according to the present embodiment. 1-kestose is also contained in vegetables, fruits, grains, etc., such as onion, garlic, banana, barley, and rye. Therefore, extracts derived from these organisms may be used as the formulation components.

[0029] As an example of an industrial method for producing 1-kestose, it can be produced by performing an enzyme reaction using sucrose as a substrate, as disclosed in JP-A-58-201980. Specifically, first, β-fructofuranosidase is added to a sucrose solution, and the solution is left to stand at 37°C to 50°C for about 20 hours to perform the enzyme reaction, thereby obtaining an enzyme reaction solution. Since this enzyme reaction solution contains a considerable amount of 1-kestose, this sugar solution may be used as a formulation component.

[0030] Alternatively, the enzyme reaction solution can be subjected to a chromatographic separation method as disclosed in JP-A-2000-232878 to separate and purify 1-kestose from other sugars (glucose, fructose, sucrose, and oligosaccharides of tetrasaccharide or more, etc.), thereby obtaining a relatively high-purity 1-kestose solution. This solution may be used as a formulation ingredient. Alternatively, the 1-kestose solution can be concentrated and then crystallized by a crystallization method as disclosed in JP-B-6-70075 to obtain 1-kestose crystals or a composition containing 1-kestose with a purity of 98% by mass or more. This crystal or composition may be used as a formulation ingredient. Note that "purity" here means the mass % of 1-kestose in the total mass of sugars. Alternatively, 1-kestose purified or further crystallized from commercially available fructooligosaccharides by the above-mentioned method may be used as a formulation ingredient.

[0031] 1-kestose can be analyzed by a method suitable for the condition of the analytical sample among commonly known analytical methods, and a method usually selected by a person skilled in the art depending on the condition of the analytical sample can be used. In a common method, the content of 1-kestose can be analyzed by dissolving the analytical sample in water, or diluting a liquid sample with water as necessary, and subjecting it to high performance liquid chromatography (HPLC) to analyze the sugar composition. The content of 1-kestose can also be calculated by taking the ratio of the peak area in the chromatogram as the mass ratio.

[0032] Next, the nutritional components that can be combined with 1-kestose are specific nutritional components such as dietary fiber, polyphenols, vitamins, lipids, amino acids, proteins, or minerals, and by combining at least one of these components with 1-kestose, a synergistic or countervailing effect of promoting the growth of bifidobacteria can be obtained. Note that the vitamins referred to here are meant to include vitamins and their derivatives as well as their salts.

[0033] Among the nutritional components, dietary fiber includes isomaltodextrin, glucomannan, levan, and β-glucan. All of these are known nutritional components and are commercially available, and products that are distributed with a label containing the name of each component, including its alternative name, are at least included in the dietary fiber components referred to here. Some of the components exist in nature; for example, glucomannan is found in konjac, and levan is found in plants of the Gramineae family, such as wheat and barley, and plants of the Liliaceae family, and is also produced by bacteria of the Serratia genus, such as Serratia levanicum. β-glucan is also found in various plants, mushrooms, and microorganisms such as Saccharomyces cerevisiae (yeast). Therefore, extracts and products derived from these organisms may be used as formulation components. For example, konjac flour, which is made by milling konjac root, contains a considerable amount of glucomannan, and such biologically processed products may be used as ingredients in formulations.

[0034] Levan is a linear fructan in which fructose is polymerized to the fructose of sucrose via a β(2,6) bond, but the main chain of β(2,6) bonds may have a branched chain of β(2,1) bonds. For example, it can be produced by the method described in JP 2002-017390 A. β-glucan is a polysaccharide in which glucose is polymerized via a β-glucoside bond, and β-glucan as a nutritional component may be β-1,3-glucan or β-(1,3)(1,4)-glucan, and may have a branched chain of β(1,6) bonds. For example, it can be produced by the method described in JP 2008-220172 A. Glucomannan is a polysaccharide in which glucose and mannose are bonded via a β(1,4) bond at a predetermined ratio, and the extraction technique from konjac root is a well-known technique, and it can be produced by the method described in JP 56-134972 A.

[0035] Isomaltodextrin is a type of hyperbranched α-glucan with a higher proportion of branched structures of α(1,6) glucoside bonds than normal dextrin. That is, so-called normal dextrin obtained by hydrolyzing normal starch by a known method is a polysaccharide in which glucose is polymerized with α(1,4) glucoside bonds and is an α-glucan with branched chains of α(1,6) glucoside bonds, whereas isomaltodextrin is a dextrin with a higher proportion of branched structures of α(1,6) glucoside bonds than normal dextrin. As exemplified in, for example, International Publication No. 2008 / 136331, isomaltodextrin is produced by synthesizing α(1,6) glucoside bonds by the transfer reaction of α-glucosyltransferase using maltose and / or α-1,4-glucan with a glucose polymerization degree of 3 or more as substrates, and α-amylase, starch debranching enzyme, etc. are also used appropriately in combination. As mentioned above, products that are distributed with labeling that includes the names of each ingredient, including alternative names, are at least included in each of the dietary fiber ingredients referred to here.

[0036] Among the nutritional components, polyphenols include rutin, quercetin, catechin, hesperidin, daidzein, p-coumaric acid, caffeic acid, and vanillin. Caffeic acid may be called caffeic acid or caffeic acid, and vanillin may be called vanillin. All of these are known nutritional components and are commercially available, and products that are distributed with the names of each component, including their alternative names, are at least included in the polyphenol components referred to here. Each component is also contained in plants, and their extracts or products may be used as formulation components.

[0037] The catechins referred to here include catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, and epigallocatechin gallate, and it is sufficient to have at least one of these. When two or more types are contained, the content of catechins refers to the total amount of all the types contained.

[0038] Polyphenols may also be modified as glycosides. That is, rutin is a quercetin glycoside, and hesperidin is a flavanone glycoside. However, quercetin, daidzein, p-coumaric acid, caffeic acid, and vanillin can also exist as glycosides in plants, etc., and therefore these polyphenol components contained in extracts or products of plants, etc. may be used as formulation ingredients in the form of glycosides.

[0039] According to the examples described later, compared with flavonoids (flavonols (rutin, quercetin), flavanols (catechin), flavanones (hesperidin)) and isoflavones (daidzein), p-coumaric acid, caffeic acid, and vanillin exhibited relatively more favorable synergistic or countervailing effects on the growth of bifidobacteria.

[0040] Among the nutritional components, vitamins include water-soluble vitamins such as biotin, niacin, pantothenic acid, and riboflavin, as well as derivatives of these vitamins and salts of the vitamins and derivatives.

[0041] Niacin here includes nicotinic acid and nicotinamide. Also, vitamin derivatives and salts are not particularly limited as long as they are normally used in food, medicine, etc. For example, in the case of riboflavin, derivatives include riboflavin esters such as riboflavin phosphate, riboflavin acetate, riboflavin butyrate, and flavin adenine dinucleotide, and salts include riboflavin sodium phosphate, flavin sodium adenine dinucleotide, etc.

[0042] Biotin is sometimes called vitamin B7, niacin is called vitamin B3, pantothenic acid is called vitamin B5, and riboflavin is called vitamin B2 or lactoflavin. All of these are known nutrients and are commercially available, and products that are distributed with the names of each ingredient, including their alternative names, are at least included in the vitamin ingredients referred to here. There is no restriction on whether the vitamins are natural or synthetic.

[0043] Furthermore, vitamins include fat-soluble vitamins such as vitamin E and vitamin D, as well as derivatives of these vitamins and salts of the vitamins and the derivatives.

[0044] Vitamin E includes tocopherol and tocotrienol, including α-tocopherol, β-tocopherol, γ-tocopherol, σ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, and σ-tocotrienol. It may be either d-form or dl-form. Vitamin D includes ergocalciferol, which is vitamin D2, and cholecalciferol, which is vitamin D3. In addition, the vitamin derivatives and salts are not particularly limited as long as they are normally used in foods, medicines, etc. For example, in the case of vitamin E, derivatives such as acetate, nicotinate, and phosphate of tocopherol or tocotrienol, and in the case of vitamin D, derivatives such as sulfate of ergocalciferol or cholecalciferol, and further salts thereof, etc. are exemplified. Both vitamin E and vitamin D are known nutritional components and commercially available products are available, and products distributed with the names of each component, including their alternative names, are at least included in the vitamin components referred to here. There is no limitation as to whether the vitamins are natural or synthetic.

[0045] According to the examples described later, compared with fat-soluble vitamins (vitamin E and vitamin D), water-soluble vitamins (vitamin B: biotin, niacin, pantothenic acid, and riboflavin) showed relatively more favorable synergistic or countervailing effects on the growth of bifidobacteria.

[0046] Among the nutritional components, lipids include arachidonic acid and α-linolenic acid. Both are known nutritional components and are commercially available. Products that are distributed under labels that include the names of the respective components, including their alternative names, at least include the respective lipid components referred to here.

[0047] In addition, lipids include compounds having arachidonic acid and α-linolenic acid as constituent fatty acids. Compounds having these fatty acids as constituent fatty acids are not particularly limited as long as they are normally used in foods, medicines, etc. For example, oils and fats containing arachidonic acid or α-linolenic acid as constituent fatty acids at a relatively high concentration (for example, perilla oil, linseed oil, perilla oil, etc., containing α-linolenic acid at a relatively high concentration), esters of the fatty acids, particularly triglycerides containing arachidonic acid, phospholipids, glycolipids, and other arachidonic acid salts, etc., are exemplified.

[0048] Among the nutritional components, the amino acid includes γ-aminobutyric acid (GABA), and the proteins include soy protein, whey protein, and lactoferrin. Soy protein is a protein derived from soybeans. Whey protein is a protein other than casein contained in milk-derived proteins (milk proteins). Lactoferrin is an iron-binding glycoprotein contained in milk (whey) and other external secretions such as tears, sweat, and saliva. All of these are known nutritional components and are commercially available, and products that are distributed with labels that include the names of each component, including their alternative names, contain at least the amino acid components or protein components referred to here.

[0049] Among the nutritional components, minerals include calcium and potassium. These minerals may be contained in the liquid preparation as ions. The mineral source used as the preparation component is not particularly limited as long as it is acceptable for incorporation into food or medicine. Examples of calcium sources include calcium lactate, calcium carbonate, calcium acetate, calcium chloride, calcium phosphate, calcium gluconate, calcium ascorbate, calcium glutamate, etc. Examples of potassium sources include potassium lactate, potassium carbonate, potassium chloride, potassium phosphate (potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate), potassium gluconate, potassium ascorbate, potassium glutamate, etc. All of these minerals (mineral sources) are known nutritional components and commercially available products exist, and products distributed under the labeling including each component name including its alternative name at least include each mineral component as referred to herein.

[0050] The nutritional components according to the present embodiment include, in addition to those specifically mentioned, derivatives of each component, salts of each component and derivatives, intermediates, precursors, and other compounds containing each component, within the scope that can be understood by a person skilled in the art to be formulated for the purpose of ingestion (administration) of the nutritional components. In addition, each nutritional component can be analyzed by a method suitable for the condition of the analysis sample among commonly known analytical methods, and a method usually selected by a person skilled in the art according to the condition of the analysis sample can be used.

[0051] The bifidobacteria growth promoter according to the present embodiment (hereinafter, the present agent) is not limited to ingredients other than 1-kestose and the specified nutritional components defined as contained ingredients, and may contain other nutritional components (sugars, dietary fiber, polyphenols, vitamins, vitamin-like substances, lipids, amino acids, proteins, minerals, etc.), other food ingredients, medicinal ingredients, herbal medicines, etc. The present agent can be provided as a prebiotic containing 1-kestose and the specified nutritional components. By ingesting (administering) this, the growth of bifidobacteria normally present in the intestine can be promoted. Alternatively, by adding bifidobacteria as probiotics to 1-kestose and the specified nutritional components as prebiotics, the present agent can be provided as a synbiotic containing 1-kestose, the specified nutritional components, and bifidobacteria. By ingesting (administering) this, the growth of the ingested (administered) bifidobacteria and bifidobacteria normally present in the intestine can be promoted.

[0052] In addition, the dosage form of the present agent is not limited, and for example, it can be appropriately formed into oral solid preparations (including supplements) such as tablets, granules, powders, and capsules, oral liquid preparations such as oral liquids and syrups, and parenteral liquid preparations such as injections. In addition, an appropriate drug delivery system (DDS) may be applied. It can be appropriately formed and formulated into each dosage form by known methods, and additives such as excipients, binders, lubricants, colorants, disintegrants, thickeners, preservatives, stabilizers, and pH adjusters that are usually added during forming and formulation may be included in the present agent. In addition, the administration method of the present agent is not limited, and oral administration, intravenous administration, intraperitoneal administration, intradermal administration, sublingual administration, local administration, etc. can be appropriately selected. In addition, it may be administered once or multiple times per day.

[0053] In addition, the agent itself can be applied as a food, a medicine, etc. Alternatively, the agent can be applied as a food composition, a medicine composition, etc. That is, when the agent is applied as a composition, it can take the form of a food, a medicine, etc. containing the agent as a composition. In other words, it can take the form of a food, a medicine, etc. containing the agent as a composition. The term "medicine" as used herein means the medicines specified in Article 2, paragraph 1 of the Law on Ensuring Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc., excluding the parentheses at the end of paragraphs 2 and 3 of the same paragraph, i.e., including quasi-drugs. The term "food" as used herein means anything that is eaten or drunk, including beverages.

[0054] When this agent is applied as a food or food composition, the food which is this agent or the food which contains this agent can be applied as a food to be taken for the purpose of promoting the proliferation of bifidobacteria and the health function equivalent thereto. In other words, it may be applicable as a product which displays or claims a specific health function as a food for specified health use under the Health Promotion Act or a food with functional claims under the Food Labeling Act.

[0055] In addition, the form of the product containing the agent as a composition is not limited. That is, the food, medicine, etc. containing the agent as a composition may also be in the form of oral solid preparations (including supplements) such as tablets, granules, powders, capsules, etc., oral liquid preparations such as oral liquids and syrups, and parenteral liquid preparations such as injections, like the agent. Therefore, a preparation containing 1-kestose and a nutritional component may be a food, medicine, etc. containing the agent as a composition, as well as a food, medicine, etc. containing the agent as a composition.

[0056] Furthermore, 1-kestose is also contained in foods that humans ingest on a daily basis, is a substance that has been consumed since ancient times, and has not been found to be toxic or mutagenic in toxicity tests and genotoxicity tests, so it can be used as a food ingredient with high safety (Food and Development, December 2014, Vol. 49, No. 12, p. 8-10). Therefore, the present agent may contain 1-kestose and may be ingested (administered) in an amount exceeding the amount at which the proliferation-promoting effect of bifidobacteria was confirmed in the examples described below. On the other hand, nutritional components with a tolerable upper limit must be ingested (administered) within a range not exceeding the tolerable upper limit, but in the examples described below, the proliferation-promoting effect of bifidobacteria was obtained by combining any of the nutritional components according to this embodiment with 1-kestose within a range not exceeding the tolerable upper limit.

[0057] In addition, 1-kestose has extremely low hygroscopicity and excellent solubility and heat resistance, making it highly convenient for food processing, and has a sweetness similar to that of sugar, so it can be used as a sugar substitute. Taking advantage of these properties of 1-kestose, foods containing the agent as a composition can be suitably applied as various foods, such as gums, gummies, candies and other confectioneries, flake- or puff-shaped cereals, bars, jellies, drink jellies, swallowable foods, beverages, etc., containing 1-kestose and a specified nutritional component. EXAMPLES

[0058] A culture test of bifidobacteria was conducted in a system containing 1-kestose and certain nutritional components. The following 1-kestose and nutritional components were used in the test (note that product names will not be listed for those sold under the names of the components or reagents themselves). 1-Kestose (iKes Crystal (registered trademark) (purity 95% by mass), Itochu Sugar Co., Ltd.) Dietary fiber: isomaltodextrin (Hayashibara Co., Ltd.), glucomannan (Rheox LM (registered trademark), Shimizu Chemical Co., Ltd.), levan (Sigma-Aldrich Japan LLC), β-glucan (Kururu's β-Glu (registered trademark), Itochu Sugar Co., Ltd.) Polyphenols: Rutin (Tokyo Chemical Industry Co., Ltd.), Quercetin (Tokyo Chemical Industry Co., Ltd.), Catechin (Tokyo Chemical Industry Co., Ltd.), Hesperidin (Fujifilm Wako Pure Chemical Industries Co., Ltd.), Daidzein (Fujifilm Wako Pure Chemical Industries Co., Ltd.), p-Coumaric acid (Fujifilm Wako Pure Chemical Industries Co., Ltd.), Caffeic acid (Tokyo Chemical Industry Co., Ltd.), Vanillin (Tokyo Chemical Industry Co., Ltd.) Vitamins: Biotin (FUJIFILM Wako Pure Chemical Industries, Ltd.), Niacin (FUJIFILM Wako Pure Chemical Industries, Ltd.), Pantothenic Acid (FUJIFILM Wako Pure Chemical Industries, Ltd.), Riboflavin (FUJIFILM Wako Pure Chemical Industries, Ltd.), α-Tocopherol (FUJIFILM Wako Pure Chemical Industries, Ltd.), Cholecalciferol (FUJIFILM Wako Pure Chemical Industries, Ltd.) Lipids: Arachidonic acid (Fujifilm Wako Pure Chemical Industries, Ltd.), α-linolenic acid (Fujifilm Wako Pure Chemical Industries, Ltd.) Amine acids, proteins: γ-aminobutyric acid (FUJIFILM Wako Pure Chemical Industries, Ltd.), soy protein (Solpro 741 (isolated soy protein), Sunbright Co., Ltd.), whey protein (THERMAX 690, Nissei Kyoeki Co., Ltd.), lactoferrin (Bioferrin 2000, Nissei Kyoeki Co., Ltd.) Minerals: Calcium chloride (FUJIFILM Wako Pure Chemical Industries, Ltd.), Dipotassium hydrogen phosphate (FUJIFILM Wako Pure Chemical Industries, Ltd.)

[0059] The medium was prepared as follows. The basal medium was prepared by dissolving 10 g of TPY medium (hypopolypeptone, Nippon Pharmaceutical Co., Ltd.), 5 g of yeast extract (Becton Dickinson and Company, Japan), 2 g of Tween 80 (Tokyo Chemical Industry Co., Ltd.), 3 g of K2HPO4 (Fujifilm Wako Pure Chemical Industries, Ltd.), 1 g of L-cysteine ​​hydrochloride hydrate (Fujifilm Wako Pure Chemical Industries, Ltd.), 2.6 g of MgSO4·7H2O (Fujifilm Wako Pure Chemical Industries, Ltd.), 0.3 g of CaCl2 (Fujifilm Wako Pure Chemical Industries, Ltd.), 6 mg of FeCl3·6H2O (Fujifilm Wako Pure Chemical Industries, Ltd.), and 2 mL of resazurin sodium salt (Tokyo Chemical Industry Co., Ltd.) adjusted to 1 mg / L in 1 L of water.

[0060] A 96-deep well plate was filled with 500 μL of TPY medium, and further with serially diluted 1-kestose, the main agent, and each nutrient component, the combined agent, and an appropriate amount of water, totaling 1 mL to the concentrations shown in Table 1, to prepare [Kes + nutrient component-added medium] (verification medium d). In addition, the nutrient component (solution) portion of verification medium d was replaced with water [Kes-added medium] (verification medium c), the 1-kestose (solution) portion of verification medium d was replaced with water [nutrient component-added medium] (verification medium b), and a suitable amount of water was added to 500 μL of TPY medium to make a total of 1 mL [supplement-free medium] (verification medium a). As a result, the following four test sections were set up. Test group a (verification medium a): TPY medium + water (supplement-free medium) Test group b (verification medium b): TPY medium + nutrients + water (nutrient-supplemented medium) Test group c (verification medium c): TPY medium + 1-kestose + water (Kes-supplemented medium) Test group d (verification medium d): TPY medium + 1-kestose + nutrients + water (Kes + nutrients added medium)

[0061] [Table 1]

[0062] The bifidobacteria used to verify the proliferation promotion were Bifidobacterium bifidum (JCM 1209), Bifidobacterium longum (JCM 1217), and Bifidobacterium infantis (JCM 1222) provided by RIKEN BRC-JCM. TPY medium containing 0.5% by mass of glucose as a carbon source was used as the pre-culture medium, and after culturing the three types of bacteria for 16 to 24 hours, 20 μL of each was inoculated into each verification medium (2% by mass per 1 mL of medium) and cultured.

[0063] The amount of bifidobacteria growth was measured and calculated 24 hours and 48 hours after the start of culture. Specifically, the amount of turbidity increase, which represents the net turbidity calculated by subtracting the turbidity measurement value at the start of culture as a blank value from the turbidity measurement value of each test medium at 24 hours and 48 hours after the start of culture, was taken as the amount of bifidobacteria growth in each test medium at that time. Turbidity was measured using a plate reader (Sunrise Rainbow, Tecan) at an absorbance wavelength of 660 nm. In addition, the turbidity at the start of culture was measured for each test medium before inoculation.

[0064] Based on the calculated amount of bifidobacteria proliferation, the effect of promoting the proliferation of bifidobacteria was evaluated. The proliferation promotion effect was evaluated according to the above-mentioned provisions of the main text. [(growth-promoting or growth-inhibiting effect when Kes is used in combination with a nutritional component) / (growth-promoting or growth-inhibiting effect when only a nutritional component is added)] The formula (d / c) / (b / a) was calculated (here, d represents the amount of growth in test plot d (verification medium d), c represents the amount of growth in test plot c (verification medium c), b represents the amount of growth in test plot b (verification medium b), and a represents the amount of growth in test plot a (verification medium a)). When (b / a) ≧ 1.00, it was determined that (d / c) / (b / a) > 1.00 was satisfied, and when (d / c) > 1.00, it was determined that there was a synergistic effect of promoting the proliferation of bifidobacteria. In addition, when (b / a) < 1.00, (d / c) / (b / a) > 1.00 is satisfied, and when (d / c) > 1.00, it is evaluated as a countervailing effect on promoting the growth of bifidobacteria. Furthermore, the degree of synergistic or countervailing effect of promoting the proliferation of bifidobacteria was classified according to the following criteria. If (d / c) / (b / a) = 1.00 or less: no effect (blank) = Above 1.00 and below 1.05: Effective (+) = 1.05 or more but less than 1.10: Effective (++) = 1.10 or more and less than 1.20: Effective (+++) = 1.20 or more and less than 2.00: Effective (*) = 2.00 or more: Effective (**) The results are shown in Tables 2 to 7.

[0065] [Table 2]

[0066] As shown in Table 2, the combined use of isomaltodextrin, glucomannan, levan, and β-glucan at a ratio of 5 mg / mL with 1-kestose at 5 mg / mL each exhibited synergistic or countervailing effects on the growth of bifidobacteria.

[0067] [Table 3]

[0068] As shown in Table 3, the combination of rutin at a ratio of 20 μg / mL or more, quercetin at a ratio of 100 μg / mL, catechin at a ratio of 2 μg / mL to 20 μg / mL, hesperidin at a ratio of 2 μg / mL or more, daidzein at a ratio of 100 μg / mL, p-coumaric acid at a ratio of 2 μg / mL or more, caffeic acid at a ratio of 2 μg / mL or more, and vanillin at a ratio of 2 μg / mL or more with respect to 5 mg / mL of 1-kestose each exhibited synergistic or countervailing effects on the growth of bifidobacteria.

[0069] Compared with flavonoids (flavonols (rutin, quercetin), flavanols (catechin), flavanones (hesperidin)) and isoflavones (daidzein), p-coumaric acid, caffeic acid and vanillin exerted relatively more favorable synergistic or countervailing effects on the growth of bifidobacteria.

[0070] [Table 4]

[0071] As shown in Table 4, the combination of biotin at a ratio of 0.1 μg / mL or more, niacin at a ratio of 17 μg / mL or more, pantothenic acid at a ratio of 2 μg / mL or more, riboflavin at a ratio of 0.5 μg / mL or more, α-tocopherol at a ratio of 2 μg / mL or more, and cholecalciferol at a ratio of 100 μg / mL with 1-kestose at 5 mg / mL each exhibited synergistic or countervailing effects on promoting the growth of bifidobacteria.

[0072] Compared with fat-soluble vitamins (α-tocopherol and cholecalciferol), water-soluble vitamins (vitamin B group: biotin, niacin, pantothenic acid, and riboflavin) exhibited relatively more favorable synergistic or countervailing effects on the proliferation of bifidobacteria. In particular, pantothenic acid exhibited a favorable synergistic or countervailing effect on the proliferation of bifidobacteria.

[0073] [Table 5]

[0074] As shown in Table 5, the combination of arachidonic acid at a ratio of 20 μg / mL or more with 1-kestose 5 mg / mL, and the combination of α-linolenic acid at a ratio of 2 μg / mL or more with 1-kestose 5 mg / mL showed synergistic or countervailing effects on the growth of bifidobacteria.

[0075] [Table 6]

[0076] As shown in Table 6, the combined use of 5 mg / mL 1-kestose with γ-aminobutyric acid at a ratio of 2 μg / mL or more, with soy protein at a ratio of 500 μg / mL, with whey protein at a ratio of 500 μg / mL or more, and with lactoferrin at a ratio of 2000 μg / mL each exhibited synergistic or countervailing effects on the proliferation of bifidobacteria. In particular, γ-aminobutyric acid exhibited a favorable synergistic or countervailing effect on the proliferation of bifidobacteria.

[0077] [Table 7]

[0078] As shown in Table 7, the combined use of 1-kestose at 5 mg / mL with calcium chloride at a ratio of 3 mg / mL and with dipotassium hydrogen phosphate at a ratio of 6 mg / mL or more exhibited synergistic or countervailing effects on the growth of bifidobacteria. In particular, dipotassium hydrogen phosphate exhibited a favorable synergistic or countervailing effect on the growth of bifidobacteria.

[0079] Although the data supporting the present invention is shown here, nutritional components other than those shown here were also tested. These did not necessarily exhibit a synergistic or countervailing effect on promoting the proliferation of bifidobacteria, which shows that the present invention (the invention related to the claims) is a combination that is the result of extensive research based on the verification of various nutritional components.

Claims

1. A synergistic or counteractive growth promoter for bifidobacteria, comprising 1-kestose and a nutritional component, The bifidobacterium growth promoter, wherein the nutritional component is one or more types of dietary fiber selected from isomaltodextrin, glucomannan, levan, and β-glucan.

2. A synergistic or counteractive growth promoter for bifidobacteria, comprising 1-kestose and a nutritional component, The bifidobacterium growth promoter, wherein the nutritional component is one or more polyphenols selected from rutin, quercetin, catechin, hesperidin, daidzein, p-coumaric acid, caffeic acid, and vanillin.

3. A synergistic or counteractive growth promoter for bifidobacteria, comprising 1-kestose and a nutritional component, The bifidobacterium growth promoter, wherein the nutritional component is one or more vitamins selected from biotin, niacin, pantothenic acid, riboflavin, vitamin E, and vitamin D, derivatives of these vitamins, and salts of the vitamins and the derivatives.

4. A synergistic or counteractive growth promoter for bifidobacteria, comprising 1-kestose and a nutritional component, The bifidobacterium growth promoter, wherein the nutritional component is one or more lipids selected from arachidonic acid, α-linolenic acid, and compounds having these fatty acids as constituent fatty acids.

5. A synergistic or counteractive growth promoter for bifidobacteria, comprising 1-kestose and a nutritional component, The bifidobacterium growth promoter, wherein the nutritional component is one or more amino acids or proteins selected from γ-aminobutyric acid, soy protein, whey protein, and lactoferrin.

6. A synergistic or counteractive growth promoter for bifidobacteria, comprising 1-kestose and a nutritional component, A bifidobacterium growth promoter, wherein the nutritional component is one or more minerals selected from calcium and potassium.

7. 4. The bifidobacterium growth promoter according to claim 3, wherein said vitamin E is α-tocopherol and said vitamin D is cholecalciferol.

8. The bifidobacteria growth promoter according to any one of claims 1 to 7, which is a synbiotic containing bifidobacteria in addition to the 1-kestose and the nutritional components.

9. A food or medicine comprising the bifidobacterium growth promoter according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Oligosaccharide for bifidobacterium proliferation

    JP2005306781A